Healthcare Analysts discuss regulatory landscape for AAV-based gene therapies (relevant companies (SLDB, TSHA, BNTC, SRPT, QURE, NTLA, CRSP, PRME) on an Analyst/industry conference calll on November 21.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Strategic Advancements and Growth Potential: Solid Biosciences’ Buy Rating Validated by Key Partnerships and Regulatory Progress
- Solid Biosciences announces licensing agreement with Andelyn Biosciences
- Solid Biosciences announces SGT-003 granted an Innovation Passport under ILAP
- Solid Biosciences price target lowered to $11 from $13 at JPMorgan
- Solid Biosciences price target lowered to $14 from $16 at Citi